期刊
JOURNAL OF GENERAL VIROLOGY
卷 95, 期 -, 页码 301-306出版社
SOC GENERAL MICROBIOLOGY
DOI: 10.1099/vir.0.058461-0
关键词
-
资金
- Krembil Foundation
- Canadian Institutes of Health Research (CIHR)
- Bill and Melinda Gates Foundation
The majority of infections, including those caused by respiratory syncytial virus (RSV), occur at mucosa! surfaces. As no RSV vaccine is available our goal is to produce an effective subunit vaccine with an adjuvant suitable for mucosal delivery and cross-presentation. A truncated secreted version of the RSV fusion (Delta F) protein formulated with polyl : C, an innate defence regulator peptide and polyphosphazene, induced local and systemic immunity, including affinity maturation of RSV F-specific IgG, IgA and virus-neutralizing antibodies, and F-specific CD8(+) T-cells in the lung, when delivered intranasally. Furthermore, this Delta F protein formulation promoted the production of CD8(+) central memory T-cells in the mediastinal lymph nodes and provided protection from RSV challenge. Formulation of Delta F protein with this adjuvant combination enhanced uptake by lung dendritic cells and trafficking to the draining lymph nodes. The Delta F protein formulation was confirmed to be highly efficacious and safe in cotton rats.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据